title: Lessons learned from marketed and investigational prodrugs.
authors.affiliation: Novartis Institute for BioMedical Research, Brunnerstrasse 59, A-1235 Vienna, Austria. peter.ettmayer@pharma.novartis.com
authors.forename: Peter
authors.initials: P
authors.lastname: Ettmayer
authors.forename: Gordon L
authors.initials: GL
authors.lastname: Amidon
authors.forename: Bernd
authors.initials: B
authors.lastname: Clement
authors.forename: Bernard
authors.initials: B
authors.lastname: Testa
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D001682:Biological Availability; D001692:Biological Transport; D002352:Carrier Proteins / Q000378:metabolism; D004337:Drug Carriers; D016503:Drug Delivery Systems; D015195:Drug Design; D015507:Drugs, Investigational / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D007408:Intestinal Absorption; D011355:Prodrugs / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D012995:Solubility
chemical_list: D000970:Antineoplastic Agents; D002352:Carrier Proteins; D004337:Drug Carriers; D015507:Drugs, Investigational; D011355:Prodrugs